18-Apr-2024
No headlines found.
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Business Wire (Fri, 22-Mar 8:05 AM ET)
Business Wire (Wed, 13-Mar 8:05 AM ET)
Business Wire (Wed, 13-Mar 8:01 AM ET)
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
Business Wire (Tue, 12-Mar 6:30 PM ET)
Tonix Pharmaceuticals Pioneering in the shifting landscape of the Dynamic CNS Therapeutics Market
Globe PR Wire (Tue, 13-Feb 4:50 AM ET)
Business Wire (Mon, 12-Feb 8:05 AM ET)
Business Wire (Mon, 5-Feb 6:01 PM ET)
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.
Sangamo Therapeutics trades on the NASDAQ stock market under the symbol SGMO.
As of April 18, 2024, SGMO stock price declined to $0.49 with 1,699,471 million shares trading.
SGMO has a beta of 1.95, meaning it tends to be more sensitive to market movements. SGMO has a correlation of 0.03 to the broad based SPY ETF.
SGMO has a market cap of $98.80 million. This is considered a Micro Cap stock.
Last quarter Sangamo Therapeutics reported $2 million in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-6 million and missed earnings estimates by -$.08.
In the last 3 years, SGMO stock traded as high as $12.83 and as low as $.29.
The top ETF exchange traded funds that SGMO belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
SGMO has underperformed the market in the last year with a price return of -72.1% while the SPY ETF gained +22.3%. However, in the short term, SGMO had mixed performance relative to the market. It has outperformed in the last 3 months, returning +9.1% vs +6.1% return in SPY. But in the last 2 weeks, SGMO shares have been beat by the market, returning -20.5% compared to an SPY return of -3.8%.
SGMO support price is $.47 and resistance is $.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SGMO stock will trade within this expected range on the day.